

04-25-05

JFW

Docket 17322 CON2CIP1 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of
EVAN B. DREYER

Serial No: 10/734,930

Filed: December 12, 2003

For: CALCIUM BLOCKERS TO
TREAT PROLIFERATIVE RETINAL
DISEASES

Group Art Unit: 1614

Examiner: Fay, Zohreh A (parent appl.)

Confirmation No. 2241

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled **CALCIUM BLOCKERS TO TREAT PROLIFERATIVE RETINAL DISEASES**, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 1 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. These documents were disclosed in an International Search Report in the foreign counterpart of the above-identified application, and the International Search Report was received less than three (3)

months ago. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,



Date: April 21, 2005

Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:


Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. §1.10

I hereby certify that this Supplemental Information Disclosure Statement and additional documents enclosed herein are being deposited with the United States Postal Service on **April 21, 2005** in an envelope as "Express Mail Post Office To Addressee" mailing label number **EL980001846US** with sufficient postage for Express Mail addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Susan Bartholomew

Name of person mailing paper



Signature of person mailing paper

Date: April 21, 2005



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17322CON2CIP1 (AP)	SERIAL NO.: 10/734,930
APPLICANTS: Evan B. Dreyer, et al.	TITLE: CALCIUM BLOCKERS TO TREAT PROLIVERATIVE RETINAL DISEASES
FILING DATE: December 12, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	2003/0114772 A1	6/19/03	David, et al.	600	558	
	AB	2003/0082183 A1	5/1/03	Wheeler, et al.	424	146	
	AC	2005/0031652 A1	2/10/05	Hughes, et al.	424	400	
	AD	6,200,990 B1	3/13/01	Namil, et al.	514	320	
	AE	6,380,261 B1	4/30/02	Dreyer	514	548	
	AF	6,509,355 B1	1/21/03	Collier Jr., et al.	514	317	
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	EP 1 221 315 A1	10/07/02	EP			Yes
	BB	EP 0 903 144 A1	24/03/99	EP			Yes
	BC	WO 96/00073	04/01/96	PCT			Yes
	BD	WO 99/25350	27/05/99	PCT			Yes
	BE	WO 03/015713 A2	27/02/03	PCT			Yes
	BF						
	BG						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Kim, T.W., et al., <i>Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia</i> Korean J. Ophthalmol Vol 16: 1-7 2002 XP008043992
CB	Beers, M., et al., Ed, Published by Merck Research Laboratories, 17 th edition, The Merck Manual of Diagnosis and Therapy, 1999, pg 38, §8, Chp 101. XP002321572
CC	Block, F., et al., <i>The b-wave of the electroretinogram as an index of retinal ischemia</i> , Gne Pharmac. Vol. 30, NO. 3, pp 281-287, 1998. XP000900438
CD	

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.